Evidence map›Paper›PMID 33392449›Full record

ArticleJOR spine2020

Verteporfin treatment controls morphology, phenotype, and global gene expression for cells of the human nucleus pulposus.

Bailey V Fearing, Julie E Speer, Liufang Jing, Aravind Kalathil, Michael P Kelly, Jacob M Buchowski, Lukas P Zebala, Scott Luhmann, Munish C Gupta, Lori A Setton

Open access · goldAbstract read
In one paragraph

Article in JOR spine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. iScience · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Bailey V FearingDepartment of Biomedical Engineering Washington University in St. Louis St. Louis Missouri USA.ORCID https://orcid.org/0000-0002-9784-4693
Julie E SpeerDepartment of Biomedical Engineering Washington University in St. Louis St. Louis Missouri USA.ORCID https://orcid.org/0000-0002-2948-4550
Liufang JingDepartment of Biomedical Engineering Washington University in St. Louis St. Louis Missouri USA.
Aravind KalathilDepartment of Biomedical Engineering Washington University in St. Louis St. Louis Missouri USA.
Michael P KellyDepartment of Orthopaedic Surgery Washington University in St. Louis St. Louis Missouri USA.
Jacob M BuchowskiDepartment of Orthopaedic Surgery Washington University in St. Louis St. Louis Missouri USA.
Lukas P ZebalaDepartment of Orthopaedic Surgery Washington University in St. Louis St. Louis Missouri USA.
Scott LuhmannDepartment of Orthopaedic Surgery Washington University in St. Louis St. Louis Missouri USA.
Munish C GuptaDepartment of Orthopaedic Surgery Washington University in St. Louis St. Louis Missouri USA.
Lori A SettonDepartment of Biomedical Engineering Washington University in St. Louis St. Louis Missouri USA.
Washington University in St. Louis · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Intra-Articular Delivery of Sustained Release NF-kB Antagonists In ArthritisR01AR070975 · NIAMS · WASHINGTON UNIVERSITY · PI SETTON, LORI A. · 2017 to 2021
$1.7M
Engineering Microenvironments for the Nucleus Pulposus CellR01AR069588 · NIAMS · WASHINGTON UNIVERSITY · PI SETTON, LORI A. · 2016 to 2019
$1.2M
Cytoskeletal Regulation of Human Nucleus Pulposus Cell PhenotypeF32AR070579 · NIAMS · WASHINGTON UNIVERSITY · PI FEARING, BAILEY V · 2017 to 2018
$121k
NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA091842NIAMS NIH HHS F32 AR070579NIAMS NIH HHS R01 AR069588NIAMS NIH HHS R01 AR070975
6 · The paper itself

Abstract

Cells of the nucleus pulposus (NP) are essential contributors to extracellular matrix synthesis and function of the intervertebral disc. With age and degeneration, the NP becomes stiffer and more dehydrated, which is associated with a loss of phenotype and biosynthetic function for its resident NP cells. Also, with aging, the NP cell undergoes substantial morphological changes from a rounded shape with pronounced vacuoles in the neonate and juvenile, to one that is more flattened and spread with a loss of vacuoles. Here, we make use of the clinically relevant pharmacological treatment verteporfin (VP), previously identified as a disruptor of yes-associated protein-TEA domain family member-binding domain (TEAD) signaling, to promote morphological changes in adult human NP cells in order to study variations in gene expression related to differences in cell shape. Treatment of adult, degenerative human NP cells with VP caused a shift in morphology from a spread, fibroblastic-like shape to a rounded, clustered morphology with decreased transcriptional activity of TEAD and serum-response factor. These changes were accompanied by an increased expression of vacuoles, NP-specific gene markers, and biosynthetic activity. The contemporaneous observation of VP-induced changes in cell shape and prominent, time-dependent changes within the transcriptome of NP cells occurred over all timepoints in culture. Enriched gene sets with the transition to VP-induced cell rounding suggest a major role for cell adhesion, cytoskeletal remodeling, vacuolar lumen, and MAPK activity in the NP phenotypic and functional response to changes in cell shape.

Indexed as

cell shapeintervertebral discmechanotransductionphenotypeRNA‐sequencing

Identifiers

PMID33392449
PMCPMC7770208
OpenAlexW3046314268

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.